|
"vogel a"的相关文件
显示项目 26-35 / 35 (共2页)
<< < 1 2
每页显示[10|25|50]项目
| 國立成功大學 |
2021 |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu, A.X.;Finn, R.S.;Kang, Y.-K.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Motomura, K.;Ohno, I.;Daniele, B.;Vogel, A.;Yamashita, T.;Hsu, C.-H.;Gerken, Gerken G.;Bilbruck, J.;Hsu, Y.;Liang, K.;Widau, R.C.;Wang, C.;Abada, P.;Kudo, M. |
| 國家衛生研究院 |
2020-03 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, LT;Martinelli, E;Cheng, AL;Pentheroudakis, G;Qin, S;Bhattacharyya, GS;Ikeda, M;Lim, HY;Ho, GF;Choo, SP;Ren, Z;Malhotra, H;Ueno, M;Ryoo, BY;Kiang, TC;Tai, D;Vogel, A;Cervantes, A;Lu, SN;Yen, CJ;Huang, YH;Chen, SC;Hsu, C;Shen, YC;Tabernero, J;Yen, Y;Hsu, CH;Yoshino, T;Douillard, JY |
| 國家衛生研究院 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
|
Valle, JW;Bai, LY;Orlova, R;Van Cutsem, E;Alfonso, JA;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, HS;Denlinger, CS;Vogel, A;He, AR;Bousmans, N;Girvan, AC;Zhang, W;Walgren, RA;Carlesi, R;Oh, DY |
| 臺大學術典藏 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; CHIH-HUNG HSU; Yen Y.; Tabernero J.; Shen Y.-C.; Hsu C.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Cheng A.-L.; Martinelli E.; Chen L.-T.; Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Hsu C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chih-Hung Hsu;Yoshino T.;Douillard J.-Y.; Choo S.P.; Ho G.F.; Lim H.-Y.; Ikeda M.; Bhattacharyya G.S.; Qin S.; Pentheroudakis G. |
| 國立成功大學 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, L.-T.;Martinelli, E.;Cheng, A.-L.;Pentheroudakis, G.;Qin, S.;Bhattacharyya, G.S.;Ikeda, M.;Lim, H.-Y.;Ho, G.F.;Choo, S.P.;Ren, Z.;Malhotra, H.;Ueno, M.;Ryoo, B.-Y.;Kiang, T.C.;Tai, D.;Vogel, A.;Cervantes, A.;Lu, S.-N.;Yen, C.-J.;Huang, Y.-H.;Chen, S.-C.;Hsu, C.;Shen, Y.-C.;Tabernero, J.;Yen, Yen Y.;Hsu, C.-H.;Yoshino, T.;Douillard, J.-Y. |
| 國立成功大學 |
2020 |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen, C.-J.;Kudo, M.;Lim, H.-Y.;Hsu, C.-H.;Vogel, A.;Brandi, G.;Cheng, R.;Nitu, I.S.;Abada, P.;Hsu, Y.;Zhu, A.X.;Kang, Y.-K. |
| 國家衛生研究院 |
2019-10 |
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
|
Oh, DY;Chen, LT;He, AR;Okusaka, T;Qin, S;Chin, S;Rokutanda, N;Uchinda, H;Vogel, A;Valle, JW;Kim, H |
| 國家衛生研究院 |
2016-08 |
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma
|
Zhu, AX;Chen, D;He, W;Kanai, M;Voi, M;Chen, LT;Daniele, B;Furuse, J;Kang, YK;Poon, RT;Vogel, A;Chiang, DY |
| 國家衛生研究院 |
2014-07-02 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 國家衛生研究院 |
2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
显示项目 26-35 / 35 (共2页)
<< < 1 2
每页显示[10|25|50]项目
|
